Children’s Hospital of Philadelphia believes more patients are choosing their imaging services because of recent cost transparency efforts.
The Germany-based imaging giant is promising its equipment will work with rival's products in exchange for the determination, officials announced.
Both had publicly discussed the transaction as far back as December 2019, but COVID-19 put the blockbuster deal on hold.
It was a few years ago that the agency kept in place roadblocks to limit such exams for patients with abandoned leads for their cardiac implantable devices.
The nation's largest insurer has allegedly advocated for one CT exam over another, and physicians are urging it to put patients first, rather than any specific test.
The Israel-based startup had announced late Monday that its stockowners were unloading nearly 2.9 million shares, dragging the price downward.
Akumin Corp. allegedly administered more than 1,500 exams either without supervision or proof of such physician oversight, the DOJ said.
University of Virginia Health did so by deploying a clinical decision support system to guide ordering providers, according to a study in JACR.
The Israel-based firm had planned to ship its first 1,000 Nanox.ARCs in late 2021, but will now do so in the first quarter of 2022.
Imaging advocates praised the policy change, which took effect on Monday, Feb. 1.
Pacific Equity Partners has emerged as the frontrunner to buy the imaging group, leaping ahead of other suitors such as KKR, according to a report.
Todd Fruchterman, MD, PhD, will assume the role Feb. 1 after previously working at 3M for nearly a decade.